ANI Pharmaceuticals Inc
NASDAQ:ANIP
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
53.35
69.69
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
ANI Pharmaceuticals Inc
ANI Pharmaceuticals Inc
Selling, General & Administrative
ANI Pharmaceuticals Inc
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ANI Pharmaceuticals Inc
NASDAQ:ANIP
|
Selling, General & Administrative
-$272.4m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-32%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Selling, General & Administrative
-$22.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Selling, General & Administrative
-$8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Selling, General & Administrative
-$14.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
0%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Selling, General & Administrative
-$10.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Selling, General & Administrative
-$8.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-2%
|
|
ANI Pharmaceuticals Inc
Glance View
ANI Pharmaceuticals Inc. operates at the heart of the pharmaceutical industry with a focused strategy that blends generics with niche high-value medications. Born in the realm of specialty pharmaceuticals, the company has crafted a business model that leverages both organic growth and strategic acquisitions. This dual approach helps the company to broaden its product offerings and maintain a robust pipeline. By targeting niche markets often overlooked by larger pharmaceutical giants, ANI maximizes its opportunities in areas with less competitive congestion. Central to its operations is the manufacturing and marketing of generic prescription products that are not only critically required but also pose less risk of commoditization due to their complexity, regulatory hurdles, or limited manufacturing capabilities. Revenue generation for ANI is a sophisticated blend of manufacturing, marketing, and brand positioning. The company's infrastructure supports integrated product development, regulatory approval, and scalable manufacturing processes. This allows them to efficiently bring to market a diverse portfolio of more than a hundred products across therapeutic areas. Additionally, ANI taps into revenue streams by producing legacy branded drugs often acquired from larger players looking to offload non-core assets. These legacy products, while sometimes in smaller volumes, benefit from loyal prescriber bases and established market presence, providing a steady income for the company. In essence, ANI Pharmaceuticals thrives on navigating the intricacies of the pharmaceutical supply chain, seizing opportunities in underexplored niches and refocusing the potential of undervalued brands.
See Also
What is ANI Pharmaceuticals Inc's Selling, General & Administrative?
Selling, General & Administrative
-272.4m
USD
Based on the financial report for Sep 30, 2024, ANI Pharmaceuticals Inc's Selling, General & Administrative amounts to -272.4m USD.
What is ANI Pharmaceuticals Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-32%
Over the last year, the Selling, General & Administrative growth was -81%. The average annual Selling, General & Administrative growth rates for ANI Pharmaceuticals Inc have been -59% over the past three years , -38% over the past five years , and -32% over the past ten years .
You don't have any saved screeners yet